Product

Nadunolimab

Aliases

CAN04

1 clinical trial

1 indication

Indication

Triple-Negative Breast Cancer

Clinical trial

A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. "TRIFOUR Study"

Status: Recruiting, Estimated PCD: 2024-08-01